Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Phase 3 Study Comparing 2 Doses of CP-690,550 vs. Placebo for Treatment of Rheumatoid Arthritis

ClinicalTrials.gov ID: NCT00814307

Public ClinicalTrials.gov record NCT00814307. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 1:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of CP-690,550 Monotherapy In Patients With Active Rheumatoid Arthritis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This Phase 3 study is intended to provide evidence of the efficacy and safety of CP 690,550 when dosed 5 mg and 10 mg twice a day as monotherapy in adult patients with moderate to severe Rheumatoid Arthritis. It is intended to confirm the benefits of CP-690,550 in improving signs and symptoms and physical function that were observed in the Phase 2 Rheumatoid Arthritis studies.

Study identification

NCT ID
NCT00814307
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Pfizer
Industry
Enrollment
611 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 2009 (Type not available)
Primary completion
Jun 2010 (Actual)
Completion
Jun 2010 (Actual)
Last update posted
Jan 18, 2013

2009 – 2010

United States locations

U.S. sites
31
U.S. states
17
U.S. cities
30
Facility City State ZIP Site status
Pfizer Investigational Site Gilbert Arizona 85234 —
Pfizer Investigational Site Tucson Arizona 85704 —
Pfizer Investigational Site Hot Springs Arkansas 71913 —
Pfizer Investigational Site Jacksonville Florida 32216 —
Pfizer Investigational Site Sarasota Florida 34233 —
Pfizer Investigational Site Tampa Florida 33614 —
Pfizer Investigational Site Venice Florida 34292 —
Pfizer Investigational Site Zephyrhills Florida 33542 —
Pfizer Investigational Site Rockford Illinois 61107 —
Pfizer Investigational Site Frederick Maryland 21702 —
Pfizer Investigational Site Hyannis Massachusetts 02763 —
Pfizer Investigational Site Kalamazoo Michigan 49048 —
Pfizer Investigational Site Teaneck New Jersey 07666 —
Pfizer Investigational Site Albany New York 12206 —
Pfizer Investigational Site Olean New York 14760 —
Pfizer Investigational Site Rochester New York 14618 —
Pfizer Investigational Site Charlotte North Carolina 28210 —
Pfizer Investigational Site Rocky Mount North Carolina 27803 —
Pfizer Investigational Site Winston-Salem North Carolina 27103 —
Pfizer Investigational Site Minot North Dakota 58701 —
Pfizer Investigational Site Dayton Ohio 45408 —
Pfizer Investigational Site Bethlehem Pennsylvania 18015 —
Pfizer Investigational Site Duncansville Pennsylvania 16635 —
Pfizer Investigational Site West Reading Pennsylvania 19611-1124 —
Pfizer Investigational Site Greenville South Carolina 29601 —
Pfizer Investigational Site Myrtle Beach South Carolina 29572 —
Pfizer Investigational Site Dallas Texas 75231 —
Pfizer Investigational Site Mesquite Texas 75150 —
Pfizer Investigational Site Seattle Washington 98104 —
Pfizer Investigational Site Seattle Washington 98122 —
Pfizer Investigational Site Clarksburg West Virginia 26301 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 64 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00814307, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 18, 2013 · Synced Oct 30, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00814307 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →